YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer’s Disease

BACKGROUND: Disease-modifying therapies for Alzheimer’s disease (AD) would be most beneficial if applied during the ‘preclinical’ stage (pathology present with cognition intact) before significant neuronal loss occurs. Therefore, biomarkers that can detect AD pathology in its early stages and predic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Craig-Schapiro, Rebecca, Perrin, Richard J., Roe, Catherine M., Xiong, Chengjie, Carter, Deborah, Cairns, Nigel J., Mintun, Mark A., Peskind, Elaine R., Li, Ge, Galasko, Douglas R., Clark, Christopher M., Quinn, Joseph F., D’Angelo, Gina, Malone, James P., Townsend, R. Reid, Morris, John C., Fagan, Anne M., Holtzman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3011944/
https://ncbi.nlm.nih.gov/pubmed/21035623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopsych.2010.08.025
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados